Elmer Schabel

494 total citations
8 papers, 266 citations indexed

About

Elmer Schabel is a scholar working on Epidemiology, Hepatology and Economics and Econometrics. According to data from OpenAlex, Elmer Schabel has authored 8 papers receiving a total of 266 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Epidemiology, 4 papers in Hepatology and 3 papers in Economics and Econometrics. Recurrent topics in Elmer Schabel's work include Liver Disease Diagnosis and Treatment (5 papers), Liver Disease and Transplantation (4 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Elmer Schabel is often cited by papers focused on Liver Disease Diagnosis and Treatment (5 papers), Liver Disease and Transplantation (4 papers) and Health Systems, Economic Evaluations, Quality of Life (3 papers). Elmer Schabel collaborates with scholars based in Germany, United States and Belgium. Elmer Schabel's co-authors include Veronica Miller, Manal F. Abdelmalek, Brent A. Neuschwander‐Tetri, Vlad Ratziu, Stephen A. Harrison, S. Megnien, Arun J. Sanyal, David E. Kleiner, Quentin M. Anstee and Sven Francque and has published in prestigious journals such as Hepatology, Gut and Journal of Hepatology.

In The Last Decade

Elmer Schabel

8 papers receiving 260 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Elmer Schabel Germany	6	236	120	103	43	33	8	266
Anita Arslanow Germany	6	248 1.1×	165 1.4×	80 0.8×	21 0.5×	36 1.1×	16	279
Federica Spatola Italy	8	245 1.0×	109 0.9×	120 1.2×	25 0.6×	18 0.5×	20	287
KeeSeok Lee United States	5	183 0.8×	81 0.7×	78 0.8×	35 0.8×	38 1.2×	14	228
Jesús Rivera‐Esteban Spain	9	240 1.0×	106 0.9×	107 1.0×	49 1.1×	27 0.8×	28	278
Graciela Castro‐Narro Mexico	10	216 0.9×	114 0.9×	52 0.5×	68 1.6×	19 0.6×	35	274
Mohammad Nasser Kabbany United States	10	334 1.4×	172 1.4×	148 1.4×	74 1.7×	57 1.7×	20	385
Hans-Jörg Cordes Germany	4	249 1.1×	106 0.9×	138 1.3×	31 0.7×	28 0.8×	5	268
Ruth Sargent United States	5	266 1.1×	114 0.9×	167 1.6×	34 0.8×	32 1.0×	6	308
Georgios Kalopitas Greece	10	171 0.7×	71 0.6×	82 0.8×	17 0.4×	33 1.0×	31	262
Katherine Eberly United States	5	275 1.2×	139 1.2×	104 1.0×	55 1.3×	30 0.9×	9	328

Countries citing papers authored by Elmer Schabel

Since Specialization

Citations

This map shows the geographic impact of Elmer Schabel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elmer Schabel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elmer Schabel more than expected).

Fields of papers citing papers by Elmer Schabel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elmer Schabel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elmer Schabel. The network helps show where Elmer Schabel may publish in the future.

Co-authorship network of co-authors of Elmer Schabel

This figure shows the co-authorship network connecting the top 25 collaborators of Elmer Schabel. A scholar is included among the top collaborators of Elmer Schabel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elmer Schabel. Elmer Schabel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Pericàs, Juan M., Quentin M. Anstee, Salvador Augustín, et al.. (2024). A roadmap for clinical trials in MASH-related compensated cirrhosis. Nature Reviews Gastroenterology & Hepatology. 21(11). 809–823. 10 indexed citations

Pericàs, Juan M., Quentin M. Anstee, Salvador Augustín, et al.. (2024). Author Correction: A roadmap for clinical trials in MASH-related compensated cirrhosis. Nature Reviews Gastroenterology & Hepatology. 21(11). 824–824. 1 indexed citations

Vetter, Thorsten, Jan Regnström, Maria Tome, et al.. (2023). Patient‐reported, observer‐reported and performance outcomes in qualification procedures at the European Medicines Agency 2013–2018. British Journal of Clinical Pharmacology. 90(1). 299–312. 2 indexed citations

Danese, Silvio, Elmer Schabel, Mark Ainsworth, & Laurent Peyrin‐Biroulet. (2020). Challenges and opportunities for IBD drug development: from early stage to regulatory approval. Gut. 69(7). 1157–1161. 7 indexed citations

Glass, Oliver, Claudia Filozof, Mazen Noureddin, et al.. (2020). Standardisation of diet and exercise in clinical trials of NAFLD-NASH: Recommendations from the Liver Forum. Journal of Hepatology. 73(3). 680–693. 71 indexed citations

Cheung, Amanda, Brent A. Neuschwander‐Tetri, David E. Kleiner, et al.. (2019). Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. Hepatology. 70(5). 1841–1855. 59 indexed citations

Siddiqui, Mohammad Shadab, Stephen A. Harrison, Manal F. Abdelmalek, et al.. (2017). Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology. 67(5). 2001–2012. 109 indexed citations

Danese, Silvio, Elmer Schabel, J. Masure, Scott E. Plevy, & Stefan Schreiber. (2016). Are We Ready to Abandon Placebo in Randomised Clinical Trials for Inflammatory Bowel Disease? Pros and Cons. Journal of Crohn s and Colitis. 10(suppl 2). S548–S552. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact